News & Views - Page 19 of 53 - Telix Pharmaceuticals Limited

Telix Completes Acquisition of QSAM Biosciences and Its Bone Cancer Targeting Platform

Telix today announces the completion of the acquisition of QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP). QSAM is a United States (U.S.) based company developing therapeutic radiopharmaceuticals for primary and metastatic bone cancer

First Patient Dosed in Austrian Named Patient (Early Access) Program for TLX250-CDx, Telix’s Kidney Cancer Imaging Agent

Telix today announces that the first patient has been dosed in its named patient program in Austria for TLX250-CDx (89Zr-DFO-girentuximab, Zircaix®). TLX250-CDx is the Company’s investigational non-invasive carbonic anhydrase IX (CAIX) targeting positron emission tomography (PET) imaging agent for clear cell renal cell carcinoma (ccRCC), the most common and aggressive form of kidney cancer.

Telix to Showcase Extensive Urologic Pipeline at AUA Annual Meeting including Phase III ProstACT GLOBAL Study of TLX591

Telix today announces five oral abstract presentations featuring the Company’s late-stage theranostic programs in urology at the American Urological Association (AUA) Annual Meeting being held in San Antonio from May 3 – 6 2024.

First Patient Dosed in Special Access Scheme in Australia for TLX250-CDx, Telix’s Kidney Cancer Imaging Agent

Telix today announces that the first patient has been dosed in a Special Access Scheme (SAS) in Australia for TLX250-CDx (89Zr-DFO-girentuximab, Zircaix®) positron emission tomography (PET) imaging in clear cell renal cell carcinoma (ccRCC).

Telix at ANZSNM Annual Scientific Meeting 2024

Telix today announces five oral abstract presentations featuring the Company’s late-stage theranostic programs at the 54th Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine (ANZSNM ASM 2024), being held in Christchurch (New Zealand) from 26-28 April 2024.

Notice of Annual General Meeting 2024

Telix is pleased to provide notice that the Annual General Meeting of the Shareholders of Telix Pharmaceuticals Limited (ACN 616 620 369) will be convened on Wednesday 22 May 2024.

Q1 2024 Revenue and Business Update

Telix today provides an update on its revenue and operational performance for the quarter ended 31 March 2024 (Q1 2024).

TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation

Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has granted Fast Track designation1 for the Company’s investigational glioma imaging product, TLX101-CDx (Pixclara™2, 18F-floretyrosine or 18F-FET).

TLX250-CDx (Zircaix®) Recognised in EAU Guidelines as an Emerging Technology for the Management of RCC (Kidney Cancer)

Telix today welcomes updated guidelines from the European Association of Urology (EAU) that for the first time include TLX250-CDx (Zircaix®, 89Zr-DFO-girentuximab) as an emerging technology for the management of renal cell carcinoma (RCC).

Telix Completes Acquisition of ARTMS, and its Advanced Isotope Production Platform

Telix, today announces the completion of the acquisition of radioisotope production technology firm ARTMS Inc. (ARTMS), its advanced cyclotron-based isotope production platform, manufacturing plant and stockpile of ultra-pure rare metals required for consumable target production.